top of page

The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

Raphaël Ognar discusses the results we have seen in the NK space over recent years and how NKILT is targeting a novel pathway with its Chimeric ILT-Receptor (CIR) binding technology.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page